HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clear-cell metastatic renal cell carcinoma

A cancer of the kidney. "Clear cell" refers to the appearance of the cancer cells when viewed with a microscope. It may be associated with somatic mutations in the OGG1 gene. OMIM: 601982
Networked: 29 relevant articles (2 outcomes, 6 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Thrombocytopenia (Thrombopenia)
2. Neoplasms (Cancer)
3. Renal Cell Carcinoma (Grawitz Tumor)

Experts

1. Tarazi, Jamal: 3 articles (01/2016 - 05/2013)
2. Sternberg, Cora N: 3 articles (06/2015 - 08/2013)
3. Chen, Connie: 3 articles (01/2015 - 05/2013)
4. Guo, Jun: 3 articles (01/2015 - 08/2013)
5. Kim, Sinil: 3 articles (01/2015 - 05/2013)
6. Escudier, Bernard: 3 articles (03/2014 - 12/2012)
7. Motzer, Robert J: 3 articles (03/2014 - 05/2013)
8. Hutson, Thomas E: 3 articles (12/2013 - 05/2013)
9. Berruti, Alfredo: 2 articles (12/2020 - 06/2015)
10. Karakiewicz, Pierre I: 2 articles (12/2020 - 01/2016)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Clear-cell metastatic renal cell carcinoma:
1. Tyrosine Kinase InhibitorsIBA
2. pazopanibFDA Link
3. Sorafenib (BAY 43-9006)FDA Link
01/01/2015 - "This registrational trial evaluated the efficacy, safety, and patient-reported outcomes of axitinib versus sorafenib as a second-line treatment in Asian patients with clear-cell metastatic renal cell carcinoma (mRCC). "
12/01/2013 - "In this randomised, open-label, phase 3 trial, patients with treatment-naive, measurable, clear-cell metastatic renal-cell carcinoma from 13 countries were stratified by Eastern Cooperative Oncology Group performance status, and then randomly assigned (2:1) by a centralised registration system to receive axitinib 5 mg twice daily, or sorafenib 400 mg twice daily. "
05/01/2013 - "Eligible patients had clear cell metastatic renal cell carcinoma, progressive disease after one approved systemic treatment, and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1. 723 patients were stratified by ECOG PS and previous treatment and randomly allocated (1:1) to receive axitinib (5 mg twice daily; n=361) or sorafenib (400 mg twice daily; n=362). "
03/01/2014 - "In this multicentre phase 3 study, patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targeted therapy and one previous mTOR inhibitor were randomly assigned through an interactive voice and web response system to receive open-label dovitinib (500 mg orally according to a 5-days-on and 2-days-off schedule) or sorafenib (400 mg orally twice daily) in a 1:1 ratio. "
12/15/2012 - "This study evaluated the tolerability and antitumor activity of AMG 386, a peptibody (a peptide Fc fusion) that neutralizes the interaction of angiopoietin-1 and angiopoietin-2 with Tie2 (tyrosine kinase with immunoglobulin-like and EGF-like domains 2), plus sorafenib in patients with clear cell metastatic renal cell carcinoma (mRCC) in a randomized controlled study. "
4. Axitinib (AG 013736)IBA
01/01/2015 - "This registrational trial evaluated the efficacy, safety, and patient-reported outcomes of axitinib versus sorafenib as a second-line treatment in Asian patients with clear-cell metastatic renal cell carcinoma (mRCC). "
12/01/2013 - "In this randomised, open-label, phase 3 trial, patients with treatment-naive, measurable, clear-cell metastatic renal-cell carcinoma from 13 countries were stratified by Eastern Cooperative Oncology Group performance status, and then randomly assigned (2:1) by a centralised registration system to receive axitinib 5 mg twice daily, or sorafenib 400 mg twice daily. "
01/01/2020 - "Toxicity Management of Front-Line Pembrolizumab Combined With Axitinib in Clear Cell Metastatic Renal Cell Carcinoma: A Case Study Approach."
05/01/2013 - "Eligible patients had clear cell metastatic renal cell carcinoma, progressive disease after one approved systemic treatment, and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1. 723 patients were stratified by ECOG PS and previous treatment and randomly allocated (1:1) to receive axitinib (5 mg twice daily; n=361) or sorafenib (400 mg twice daily; n=362). "
01/01/2016 - "Axitinib, a selective and potent tyrosine kinase inhibitor of vascular endothelial growth factor receptors, was available to patients from Canada and Australia, prior to regulatory approval of axitinib in these countries, for treatment of clear-cell metastatic renal cell carcinoma (mRCC) after failure of one prior systemic regimen. "
5. TIE-2 Receptor (Receptor, TIE 2)IBA
6. Angiopoietin-2IBA
7. Angiopoietin-1IBA
8. Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
9. Peptides (Polypeptides)IBA
10. Immunoglobulins (Immunoglobulin)IBA

Therapies and Procedures

1. Therapeutics
2. Nephrectomy
3. Immunotherapy